
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is poised for growth with a validated product, potential for approval of a new drug and device, and a strong financial position, despite some legal challenges and competition in the market.
Bears say
Liquidia is facing legal uncertainty and potential competition from other companies, which could limit its ability to operate freely and continue to drive growth. Although the company has seen success with Yutrepia, there are concerns about whether it can maintain this momentum and if physicians will feel comfortable pushing the dosage beyond traditional levels in certain patient populations. Additionally, there are risks associated with the company's pipeline and the potential for unexpected outcomes from clinical trials and regulatory decisions. These factors contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares